Resources

News & Events
T2EVOLVE to be present at ASGCT’s Spotlight on IMMUNO-ONCOLOGY Conference
Project Coordinator Michael Hudecek will represent #T2EVOLVE alongside Maik Luu and Dirk Busch at ASGCT's Spotlight on Immuno-Oncology Conference on August 1-2. The event features speakers and topics including novel CAR designs and approaches beyond B-Cell...
T2EVOLVE to be present at 2nd How I Manage: CAR-T Therapies and Bispecific Antibodies for my patients
T2EVOLVE partners Ulrich Jäger and Marie José Kersten will chair the European School of Haematology (ESH) meeting: 2nd How I Manage: CAR-T Therapies and Bispecific Antibodies for my patients. Abstract submission is open until 16 July. For more information about the...
T2EVOLVE meeting HNHCP at EHA2023
T2EVOLVE met with the Haematology Nurses and Healthcare Professionals Group on day 1 at the EHA2023 Congress in Frankfurt, Germany for an opportunity to share ideas and knowledge. We will be present at the Collaboration Plaza for the remainder of the congress, and...
Join T2EVOLVE at the EHA2023 Congress
T2EVOLVE will be present at EHA2023, the annual congress of the European Hematology Association. The hybrid congress runs from June 8 to June 15 with in-person sessions taking place in Frankfurt am Main in Germany. T2EVOLVE Project Coordinator Michael Hudecek will be...
Thank you for joining us at the DG-GT workshop in Langen
T2EVOLVE thanks everyone for joining us at our roundtable discussion at the Deutsche Gesellschaft für Gentherapie e.V. (DG-GT) workshop, in Langen, Germany last week. The sessions discussing how we progress the parent-child IND concept from a regulatory point of view...
T2EVOLVE Roundtable Discussion at DG-GT on April 27
T2EVOLVE will host a roundtable discussion at the upcoming Deutsche Gesellschaft für Gentherapie e.V. (DG-GT) workshop, in Langen, Germany on April 27-28. Together with moderators Inga Schapitz and Delphine Ammar, panelists from the industry, regulatory bodies, and...

Latest Tweets

Publications
- Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
- Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
- CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models
- Targeting metabolic rewiring might decrease spread of tumor cells: Mitochondrial tRNA modifications promote cancer metastasis
- CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
- CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome

Materials
Partner perspectives
5th European CAR T-cell meeting posters
